Substrate-dependent inhibition of human mate1 by cationic ionic liquids

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 3, 2013, Pages 495-503

  Martínez Guerrero, Lucy J ^a   Wright, Stephen H ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 3 BUTYLIMIDAZOLIUM; CARRIER PROTEIN; CATION; IONIC LIQUID; MULTIDRUG AND TOXIN EXTRUDER 1 PROTEIN; MULTIDRUG AND TOXIN EXTRUDER 2K PROTEIN; N BUTYL N METHYLPYRROLIDINIUM; N BUTYLPYRIDINIUM; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CHO CELL; COMPETITIVE INHIBITION; CONTROLLED STUDY; FEMALE; KIDNEY TUBULE EXCRETION; LIGAND BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; STRUCTURAL HOMOLOGY; TRANSPORT KINETICS;

1-METHYL-4-PHENYLPYRIDINIUM; 4-CHLORO-7-NITROBENZOFURAZAN; ALGORITHMS; ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT, ACTIVE; CATIONS; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; IONIC LIQUIDS; KINETICS; ORGANIC CATION TRANSPORT PROTEINS; PYRIDINIUM COMPOUNDS; QUATERNARY AMMONIUM COMPOUNDS;

EID: 84882419834     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.204206     Document Type: Article

References (40)

1. Astorga B, Ekins S, Morales M, and Wright SH (2012) Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther 341:743-755.
2. Belzer M, MoralesM, Jagadish B, Mash MA, andWright SH (2013) Substrate-dependent ligand inhibition of the human organic cation transporter OCT2. J Pharmacol Exp Ther 346:300-310.
3. Chen Y, Zhang S, Sorani M, and Giacomini KM (2007) Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther 322:695-700.
4. Cheng Y, Martinez-Guerrero LJ, Wright SH, Kuester RK, Hooth MJ, and Sipes IG (2011) Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. Drug Metab Dispos 39: 1755-1761.
5. Cheng Y, Wright SH, Hooth MJ, and Sipes IG (2009) Characterization of the disposition and toxicokinetics of N-butylpyridinium chlor ide in male F-344 rats and female B6C3F1 mice and its transport by organic cation transporter 2. Drug Metab Dispos 37:909-916.
6. Christensen HN (1975) Biological Transport, W. A. Benjamin, Inc., London.
7. Dangprapai Y and Wright SH (2011) Interaction of H1 with the extracellular and intracellular aspects of hMATE1. Am J Physiol Renal Physiol 301:F520-F528.
8. David C, Rumrich G, and Ullrich KJ (1995) Luminal transport syste m for H1/organic cations in the rat proximal tubule. Kinetics, dependence on pH; specificity as compared with the contraluminal organic cation-transport system. Pflugers Arch 430:477-492.
9. Endres CJ, Hsiao P, Chung FS, and Unadkat JD (2006) The role of transporters in drug interactions. Eur J Pharm Sci 27:501-517.
10. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236.
11. Gorboulev V, Shatskaya N, Volk C, and Koepsell H (2005) Subtype-specific affinity for corticosterone of rat organic cation transporters rOCT1 and rOCT2 depends on three amino acids within the substrate binding region. Mol Pharmacol 67: 1612-1619.
12. Hagenbuch B (2010) Drug uptake systems in liver and kidney: a historic perspective. Clin Pharmacol Ther 87:39-47.
13. Harper JN and Wright SH (2013) Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2. Am J Physiol Renal Physiol 304: F56-F67.
14. Jonker JW and Schinkel AH (2004) Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308:2-9.
15. Karbach U, Kricke J, Meyer-Wentrup F, Gorboulev V, Volk C, Loffing-Cueni D, Kaissling B, Bachmann S, and Koepsell H (2000) Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol 279: F679-F687.
16. Kido Y, Matsson P, and Giacomini KM (2011) Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54:4548-4558.
17. Klaassen CD and Aleksunes LM (2010) Xenobiotic, bile ac id, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1-96.
18. Knudsen GA, Cheng Y, Kuester RK, Hooth MJ, and Sipes IG (2009) Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. Drug Metab Dispos 37:2171-2177.
19. Komatsu T, Hiasa M, Miyaji T, Kanamoto T, Matsumoto T, Otsuka M, Moriyama Y, and Omote H (2011) Characterization of the human MATE2 proton-coupled polyspecific organic cation exporter. Int J Biochem Cell Biol 43:913-918.
20. Lickteig AJ, Cheng X, Augustine LM, Klaassen CD, and Cherrington NJ (2008 ) Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci 83: 59-64.
21. Malo C and Berteloot A (1991) Analysis of kinetic data in transport studies: new insights from kinetic studies of Na(1)-D-glucose cotransport in human intestinal brush-border membrane vesicles using a fast sampling, rapid filtration apparatus. J Membr Biol 122:127-141.
22. Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, andInui KI (2006) Identification and functional characterization of a new human kidney-specific H1/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17:2127-2135.
23. Meijer DKF, Mol WEM, Müller M, and Kurz G (1990) Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations. J Pharmacokinet Biopharm 18:35-70.
24. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, and Inui K (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866-874.
25. Ohta KY, Inoue K, Hayashi Y, and Yuasa H (2006) Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H1 antiporter in the kidney. Drug Metab Dispos 34: 1868-1874.
26. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, and Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 102:17923-17928.
27. Pelis RM and Wright SH (2011) Renal transport of organic anions and cations. Compr Physiol 1:1795-1835.
28. Ross CR and Holohan PD (1983) Transport of organic anions and cations in isolated renal plasma membranes. Annu Rev Pharmacol Toxicol 23:65-85.
29. Schäli C, Schild L, Overney J, and Roch-Ramel F (1983) Secretion of tetraethylammonium by proximal tubules of rabbit kidneys. Am J Physiol 245: F238-F246.
30. Schomig E, Lazar A and Grundemann D (2006) Extraneuronal monoamine transporter and organic cation transporters 1 and 2: a review of transport efficiency. Handb Exp Pharmacol 175:151-180.
31. Segel IH (1975) Enzyme Kinetics, pp 100-111, John Wiley & Sons, New York.
32. Sipes IG, Knudsen GA, and Kuester RK (2008) The effects of dose and route on the toxicokinetics and disposition of 1-butyl-3-methylimidazolium chloride i n male F-344 rats and female B6C3F1 mice. Drug Metab Dispos 36:284-293.
33. Stein WD (1986) Transport and Diffusion across Cell Membranes, Academic Press, New York.
34. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, and Inui KI (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/ H(1)-organic cation antiporters. Biochem Pharmacol 74:359-371.
35. Terada T and Inui K (2008) Physiological and pharmacokinetic roles of H1/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol 75:1689-1696.
36. Tsuda M, Terada T, Asaka J, Ueba M, Katsura T, and Inui K (2007) Oppositely directed H1 gradient functions as a driving force of rat H1/organic cation antiporter MATE1. Am J Physiol Renal Physiol 292:F593-F598.
37. Vazquez-Laslop N, Zheleznova EE, Markham PN, Brennan RG, and Neyfakh AA (2000) Recognition of multiple drugs by a single protein: a trivial solution of an old paradox. Biochem Soc Trans 28:517-520.
38. Wright SH and Wunz TM (1999) Influence of substrate structure on substrate binding to the renal organic cation/H1 exchanger. Pflugers Arch 437:603-610.
39. Wright SH, Wunz TM, and Wunz TP (1995) Structure and interaction of inhibitors with the TEA/H1 exchanger of rabbit renal brush border membranes. Pflugers Arch 429:313-324.
40. Zolk O, Solbach TF, König J, and Fromm MF (2009) Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 379:337-348.